Finance

Lists
BOI:EPA
Boiron SA
18,50 €
+1,93%
(+0,35) 1D
20-окт., 10:31:41 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for BOI...
Open
18,15 €
High
18,50 €
Low
18,10 €
Mkt. cap
324,59 млн
Avg. vol.
5,50 миң
Volume
694,00
P/E ratio
12,26
52-wk high
32,00 €
52-wk low
16,90 €
EPS
1,51 €
Shares outstanding
17,55 млн
No. of employees
3 миң
Open
18,15 €
High
18,50 €
Low
18,10 €
Mkt. cap
324,59 млн
Avg. vol.
5,50 миң
Volume
694,00
P/E ratio
12,26
52-wk high
32,00 €
52-wk low
16,90 €
EPS
1,51 €
Shares outstanding
17,55 млн
No. of employees
3 миң
News stories
From web sources and news partners
ACCESS Newswire
ACCESS Newswire
·
21 мүнөт мурун
Press Release Distribution & Media Outreach Platform for PR Agencies
Simply Wall Street
Simply Wall Street
·
10 мүнөт мурун
Favourable Signals For XBP Global Holdings: Numerous Insiders Acquired Stock
Bellingham Herald
Bellingham Herald
·
12 мүнөт мурун
Nasdaq futures dip as oil prices climb, earnings loom
Seeking Alpha
Seeking Alpha
·
21 мүнөт мурун
Nasdaq futures slip as Korea tumble weighs on tech (SPX:)
Profile
Boiron is a manufacturer of homeopathic products, headquartered in France and with an operating presence in 59 countries worldwide. It is the largest manufacturer of homeopathic products in the world. In 2004, it had a workforce of 2,779 and turnover of € 313 million. It is a member of the CAC Small stock index. In June 2005, the firm acquired Dolisos Laboratories, then the world's second largest manufacturer of homeopathic preparations. Products of Boiron include mono- and poly-preparations, which Boiron refer to as "proprietary drugs". Homeopathy is a pseudoscience with no evidence of effectiveness for stated claims or plausible mechanism of medicinal effect, and several class action lawsuits have been filed on behalf of consumers claiming that Boiron's homeopathic products, including Children's Coldcalm and Oscillococcinum, are useless and Boiron's marketing of these products is deceptive. Wikipedia
About Boiron SA
CEO-
Employees2,62 миң
Founded1932-ж., 7-июн.
Headquarters-
SectorPharmaceutical industry
Websiteboiron.fr
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
127,73 млн
127,73 млн
120,16 млн
120,16 млн
Cost of goods sold
35,40 млн
35,40 млн
33,53 млн
33,53 млн
Cost of revenue
35,40 млн
35,40 млн
33,53 млн
33,53 млн
Research and development expenses
1,56 млн
1,56 млн
1,44 млн
1,44 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
79,26 млн
79,26 млн
79,95 млн
79,95 млн
Operating expense
77,52 млн
77,52 млн
81,88 млн
81,88 млн
Total operating expenses
112,92 млн
112,92 млн
115,41 млн
115,41 млн
Operating income
14,81 млн
14,81 млн
4,76 млн
4,76 млн
Other non operating income
-1,13 млн
-1,13 млн
-2,29 млн
-2,29 млн
EBT including unusual items
13,82 млн
13,82 млн
4,02 млн
4,02 млн
EBT excluding unusual items
13,16 млн
13,16 млн
2,75 млн
2,75 млн
Income tax expense
3,18 млн
3,18 млн
1,56 млн
1,56 млн
Effective tax rate
22,99%
22,99%
38,90%
38,90%
Other operating expenses
-3,30 млн
-3,30 млн
488,00 миң
488,00 миң
Net income
10,64 млн
10,64 млн
2,46 млн
2,46 млн
Net profit margin
8,33%
8,33%
2,04%
2,04%
Earnings per share
-
-
-
-
Interest and investment income
653,00 миң
653,00 миң
636,50 миң
636,50 миң
Interest expense
-335,00 миң
-335,00 миң
-410,00 миң
-410,00 миң
Net interest expenses
318,00 миң
318,00 миң
226,50 миң
226,50 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
18,06 млн
18,06 млн
11,17 млн
11,17 млн
Gain or loss from assets sale
-446,00 миң
-446,00 миң
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору